OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® ADC enabling technology
TAIPEI, Taiwan, May 01, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (“OBI”), a clinical stage oncology company(4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-902, to conduct a Phase 1/2 study. OBI plans to enroll patients with advanced solid tumors. This IND clearance represents a significant milestone for OBI-902, bringing forward a potentially best-in-class Trop-2 -targeted cancer therapy for patients with high unmet medical needs.
OBI's Chief Executive Officer, Heidi Wang, Ph.D. noted, “The impending OBI-902-001 clinical trial intends to evaluate the safety, pharmacokinetics, and preliminary efficacy of OBI-902 in patients with advanced solid tumors. We are very excited to begin dosing patients in our Phase 1/2 clinical study of OBI-902 later this year.”
OBI-902 is a novel Trop-2 ADC utilizing OBI's proprietary GlycOBI® ADC enabling technology. At the 2025 American Association for Cancer Research (AACR) meeting, OBI presented data demonstrating enhanced linker-payload stability, favorable pharmacokinetics with superior and durable antitumor activities of OBI-902 in numerous in-vitro and animal studies compared to other Trop-2 ADCs 1, 2. The Phase 1/2 clinical study is planned to begin enrolling patients in 2H 2025.
1 OBI-902, a novel TROP-2 targeted antibody-drug conjugate via GlycOBI® platform, has favorable pharmacokinetics and sustained antitumor activities in challenging solid tumors.
AACR Annual Meeting 2025 Abstracts online https://www.abstractsonline.com/pp8/#!/20273/presentation/1103
2 Harnessing the GlycOBI® enabling technologies: next-generation site-specific glycan ADCs with versatile DAR to enhance therapeutic index.
AACR Annual Meeting 2025 Abstracts online https://www.abstractsonline.com/pp8/#!/20273/presentation/3007
About OBI-902
OBI-902 is a Trop-2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload to kill tumor cells and with a drug-antibody ratio (DAR) of 4. Trop-2 is highly expressed in a variety of solid tumors such as breast, ovarian, gastric, and many other cancer types, rendering it an ideal target for cancer therapy.
OBI-902 is a novel site-specific glycan-conjugated ADC using OBI's proprietary GlycOBI® platform, which provides improved stability and enhanced hydrophilicity. OBI-902 demonstrated remarkable antitumor efficacy, improved pharmacokinetic characteristics, and a favorable safety profile in various animal models. IND of OBI-902 was submitted to the U.S. FDA on March 31, 2025, and the IND was cleared on April 30, 2025.
OBI has licensed Trop-2 targeting antibody from Biosion, Inc. (www.biosion.com) since December 2021, holding exclusive rights worldwide except in China. OBI holds worldwide commercial rights to OBI-902, to the exception of the rights pertaining to the antibody in China.
About GlycOBI®
OBI has developed a unique glycan-based ADC technology (GlycOBI®), which is in a ‘Plug and Play' format and compatible with any antibodies, linkers, and payloads in various DAR. Utilizing OBI's proprietary enzymatic technology(EndoSymeOBI®) and linker technology(HYPrOBI™), GlycOBI® generates site-specific homogenous ADCs with an efficient and scalable process under GMP conditions. The conjugation process of GlycOBI® avoids disrupting the antibody structure and ensures the ADC has similar biophysical characteristics to the native antibody. Furthermore, OBI's linker technology has improved conjugation efficiency of the payload, reduced aggregation propensity, which provides advantages on manufacturing ADC products. GlycOBI® has overcome the limitations of traditional ADCs and achieved better antitumor activity and stability in various in vivo animal studies.
About OBI Pharma
OBI is a clinical stage global oncology company that is headquartered in Taiwan and established in 2002. Its mission, together with its wholly owned subsidiary OBI Pharma USA, Inc., is to develop novel cancer therapeutic agents for patients with high unmet medical needs.
OBI's primary focus is the development of novel ADCs, including the first-generation cysteine-based TROP-2 ADC, OBI-992. Using the company's proprietary ADC enabling technology, GlycOBI®, powered by EndoSymeOBI® and HYPrOBI™; OBI has created its second generation novel ADC pipeline, including monospecific: OBI-902 (Trop-2), OBI-904 (Nectin-4), Trastuzumab-ADC (HER2), bi-specifics and dual payload ADCs. To broaden the applicability of the linker technology, HYPrOBI™, OBI further developed a next-generation ThiOBI® platform to enable irreversible cysteine-based conjugation. Additionally, OBI's pipeline also includes the first-in-class AKR1C3-targeted small-molecule prodrug OBI-3424, which selectively releases a potent DNA-alkylating antitumor agent in the presence of the aldo-keto reductase 1C3 (AKR1C3) enzyme that is highly expressed in tumors. Additional information can be found at www.obipharma.com.
GlycOBI®, EndoSymeOBI®, ThiOBI® are registered trademarks of OBI. HYPrOBI™ is a trademark under registration.
COMPANY CONTACT:
Kevin Poulos, Chief Business Officer
OBI Pharma USA, Inc.
+1 (619 537 7698, ext. 102
kpoulos@obipharma.com
- 2024年佛山市《职业病防治法》宣传周启动仪式顺利举办
- 临商银行金雀山支行开展防范非法集资宣传活动
- 馨田成功承办中国粮油学会油脂分会第三十三届学术年会暨产品展示会
- 创新引领未来,奥恒酒行树立酒类电商行业新标杆
- 品质与创新的双重奏——京视酒汇打造酒类电商购物新体验
- AI-RAN联盟宣布任命Alex Jinsung Choi博士为主席
- Regnology Acquires CG3-1 REGTECH LLC (CG3-1) to Expand North American Footprint
- 跟着诗词游庐山 选出你心中的TOP100!
- 海南省政协主席李荣灿调研宇乐乐影业
- 足力健经销商故事:从店员到拥有五家门店,坚持不懈换来水到渠成
- 彦希2024全新个人专辑《Golden Blue》圆满收官,音乐梦境吟唱人生回响
- 啄木鸟家庭维修:守护家的温暖,引领行业新风尚
- 从亚洲到全球 顺丰控股开启新一轮价值跃升
- 顾家家居首届整家经销商大会盛大开幕 八大生活方式及解决方案发布
- 喀什地区慈善总会携手爱心企业在英吉沙县开展"慈善捐赠爱心惠民
- nCino Reports Third Quarter Fiscal Year 2025 Financial Results
- WS WhatsApp萌新日记:这个营销工具让我好奇连连,究竟是什么神物
- NTLA截止日期:Rosen Law Firm敦促遭受损失超过5万美元的Intellia Therapeutics, Inc. (NASDAQ: NTLA)股东与律所联系以了解有关其权利的信息
- NTT DOCOMO:日本首次利用AI在4.8 GHz频段进行6G无线电接口室内测试,吞吐量提高多达18%
- Pacific Green Achieves Planning Consent for its Limestone Coast, South Australia, 1.5GWh Battery Ene
- 魔方网表,新一代excel服务器
- 药材好,药才好!仲景宛西制药从源头把紧中药材质量关
- Kioxia开始量产首款QLC UFS Ver. 4.0嵌入式闪存设备
- 智慧时代创新发展峰会成功举行
- 书道名师·德才兼备——书法名家张彬百家媒体聚焦报道
- 中国人寿财险溆浦县支公司 开展走访慰问退役老兵慰问活动
- 正宗云南过桥米线品牌之云谷盛宴
- 廊坊到明光长途搬家公司搬家搬运我们最专业
- The World's First International Drone Competition Will Brighten Up Nha Trang's Sky This Ju
- 农发行常德市分行:加强节前安全检查 筑牢安全生产防线
推荐
-
新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
-
奥运冠军刘翔更新社交账号晒出近照 时隔473天更新动态! 2月20日凌晨2点,奥运冠军刘翔更新社交账号晒 资讯
-
海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯
-
一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯
-
男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯
-
王自如被强制执行3383万 据中国执行信息公开网消息,近期,王自如新增一 资讯
-
中国减排方案比西方更有优势 如今,人为造成的全球变暖是每个人都关注的问 资讯
-
抖音直播“新红人”进攻本地生活领域 不难看出,抖音本地生活正借由直播向本地生活 资讯
-
透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯
-
产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯